[ad_1]
BERWYN, Pa., November 12, 2020 (GLOBE NEWSWIRE) – Annovis Bio Inc. (NYSE American: ANVS), a clinical stage pharmaceutical platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, announced today that it has successfully completed the dog cohort of a chronic toxicology study on its lead therapeutic compound ANVS401 for the treatment of AD and PD, with no adverse side effects reported.
The nine-month dog study was part of a series of animal toxicology studies, funded by a $ 1.9 million grant from the National Institutes of Health that began in the fourth quarter of 2019. Strong safety data confirms the positive results of the Society’s previous one – monthly safety studies in mice, rats, dogs and humans and six month study in rats.
Maria Maccecchini, Ph.D., CEO, commented: “The strong safety profile observed in ANVS401 in our study on chronic toxicity in dogs is another important milestone for Annovis. Our chronic toxicology studies, which are critical to enabling us to conduct long-term human studies, provide a solid foundation for ANVS401 as we continue to recruit and treat patients for our two active Phase 2a clinical trials. We intend to report provisional data on our Phase 2a clinical trials in the first quarter of 2021. “
Of Annovis Bio
Based in Berwyn, Pennsylvania, Annovis Bio, Inc. (Annovis) is a clinical-stage pharmaceutical platform company that deals with neurodegeneration, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and Alzheimer’s in Down syndrome (AD-DS). We believe we are the only company to develop a drug for AD, PD and AD-DS that inhibits more than one neurotoxic protein and thereby improves the nerve cell’s information superhighway known as axonal transport. . When this flow of information is impaired, the nerve cell becomes ill and dies. We expect our treatment to improve memory loss and dementia associated with AD and AD-DS, as well as body and brain functions in PD. We have an ongoing Phase 2a study in patients with AD and have started a second Phase 2a study in patients with AD and PD. For more information on Annovis, visit the company’s website: www.annovisbio.com.
Forward-Looking Statements
The statements contained in this press release contain “forward-looking statements” which are subject to material risks and uncertainties. Forward-looking statements contained in this press release can be identified by the use of words such as “anticipate”, “expect”, “believe”, “will”, “may”, “should”, “estimate”, “project,” ” Perspective “,” forecast “or other similar words and include, without limitation, statements regarding the timing, efficacy and expected results of the ANVS401 clinical trials. Forward-looking statements are based on the current expectations of Annovis Bio, Inc. and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. In addition, some forward-looking statements are based on assumptions about future events that may not prove accurate, including the fact that clinical trials may be delayed. These and other risks and uncertainties are described more fully in the section entitled “Risk Factors” in the Annual Report on Form 10-K for the year ended December 31, 2019 filed with the Securities and Exchange Commission. The forward-looking statements contained in this announcement are released as of this date and Annovis Bio, Inc. undertakes no obligation to update such information, except as required by applicable law.
Investor Relations:
Dave Gentry, CEO
RedChip Companies Inc.
407-491-4498
[email protected]
SOURCE: Annovis Bio, Inc.
.
[ad_2]
Source link
